Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients

Soft Tissue Sarcoma Adult Clinical Trial

— METROPHOLYS  

Official title:

The METROPHOLYS Study Metronomic Cyclophosphamide vs Doxorubicin in Elderly Patients With Advanced Soft Tissue Sarcomas Randomized, Controlled Open Label Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04656262
• Other study ID #: IOV-2018-STS-METROPHOLYS
• Status: Recruiting
• Phase: Phase 3
• Start date: September 10, 2018
• Est. completion date: January 31, 2023

Study information

• Verified date: March 2022
• Source: Istituto Oncologico Veneto IRCCS
• Contact: Gian Luca De Salvo
• Phone: 0039-049-8215710
• Email: gianluca.desalvo[@]iov.veneto.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To compare the efficacy, as measured by time to treatment failure, of metronomic cyclophosphamide with respect to doxorubicin in elderly patients affected by mSTS.

Description:

This phase III randomized clinical trial was designed to compare metronomic Cyclophosphamide with standard Doxorubicin for the first-line treatment of elderly cancer patients with advanced inoperable or metastatic STS: i) ARM A (experimental): Metronomic Cyclophosphamide ii) ARM B (control): Doxorubicin up to six cycles

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 132
• Est. completion date: January 31, 2023
• Est. primary completion date: July 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 70 Years and older

Eligibility

Inclusion Criteria:

Patients may be included in the study only if they meet all the following criteria:

1. Histologically proven diagnosis of soft tissue sarcoma.

2. Advanced unresectable or metastatic soft tissue sarcoma not previously treated with chemotherapy for metastatic disease.

3. At least one measurable lesion according to RECIST1.1 criteria.

4. Availability of a tumor sample (primary and/or metastatic sites).

5. Age = 70 years (70-75 years if UNFIT at G8; >75 independent of G8 score)

6. ECOG PS 0-2.

7. Life expectancy of at least 12 weeks.

8. Neutrophils =1.5 x 109/L, Platelets =100 x 109/L, Hgb = 9 g/dl.

9. Adequate hepatic function, defined as: Total bilirubin = 1.5 time the upper-normal limits (ULN) of the normal values, ASAT (SGOT) and/or ALAT (SGPT) = 2.5 x ULN (or <5 x ULN in case of liver metastases)

10. Alkaline phosphatase = 2.5 x ULN (or <5 x ULN in case of liver metastases).

11. Creatinine clearance = 30 mL/min.

12. Normal cardiac function, with left ventricular ejection fraction (LVEF) =50%.

13. Male subjects with female partners of childbearing potential must be willing to use adequate contraception as approved by the investigator

14. Geriatric assessment by means of G8 screening tool and CRASH score.

15. Will and ability to comply with the protocol.

16. Written informed consent to study participation.

Exclusion Criteria:

• Patients will be excluded from the study for any of the following reasons:

1. Previous treatment for metastatic disease.

2. Previous (neo) adjuvant chemotherapy with anthracyclines.

3. Radiotherapy to any site within 4 weeks before the study.

4. Untreated brain metastases or spinal cord compression or primary brain tumors.

5. Active uncontrolled infections or other clinically relevant concomitant illness contraindicating chemotherapy administration.

6. Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (=6 months), myocardial infarction (=6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF), serious cardiac arrhythmia requiring medication.

7. Treatment with any investigational drug within 30 days prior to enrollment or 2 investigational agent half-lives (whichever is longer)

8. Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of localized basal and squamous cell carcinoma or cervical cancer in situ.

9. Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication.

10. Known hypersensitivity to trial drugs or hypersensitivity to any other component of the trial drugs.

11. Any concomitant drugs contraindicated for use with the trial drugs according to the product information of the pharmaceutical companies.

12. Sexually active males unwilling to practice contraception during the study and until 6 months after the last trial treatment.

Related Conditions & MeSH terms

• Sarcoma
• Soft Tissue Sarcoma Adult

Intervention

Drug:
• Cyclophosphamide
Cyclophosphamide is formulated as coated tablets of 50mg for oral administration
• Doxorubicin
Doxorubicin is formulated as 60 mg/mq for infusional use (i.v use)

Locations

Country	Name	City	State
Italy	Istituto Ortopedico Rizzoli IRCCS	Bologna
Italy	Policlinico Sant'Orsola Malpighi	Bologna	BO
Italy	Fondazione del Piemonte per l'Oncologia IRCCS	Candiolo
Italy	IRST Romagnolo IRCCS	Meldola
Italy	Istituto Nazionale Tumori IRCCS	Milano
Italy	Istituto Oncologico Veneto IRCCS	Padova
Italy	AOU Policlinico Giaccone Palermo	Palermo
Italy	Ospedale Misericordia e Dolce	Prato
Italy	IFO - Istituto Regina Elena	Roma
Italy	Policlinico Universitario Campus Biomedico	Roma
Italy	Istituto Clinico Humanitas	Rozzano	MI
Italy	Presidio Sanitario Humanitas - Gradenico	Torino
Italy	AOUI Policlinico Borgo Roma	Verona

Sponsors (2)

Lead Sponsor	Collaborator
Istituto Oncologico Veneto IRCCS	Ministry of Health, Italy

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to treatment failure	Progressive disease is defined as per RECIST 1.1 criteria based on investigator assessment.; Toxicity is assessed according to NCI-CTCAE criteria v. 4.03	From date of randomization until the date of treatment discontinuation due to disease progression, toxicity leading to treatment discontinuation, or death, whichever occurs first, assessed up to 12 months
Secondary	Progression free Survival	Progressive disease is defined as per RECIST 1.1 criteria based on investigator assessment.	From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
Secondary	Overall survival	Overall Survival is defined as the time from date of randomization to the date of death due to any cause	Time from randomization to the date of death due to any cause or last follow up assessed up to 12 months
Secondary	Overall Toxicity Rate	Toxicities will be recorded, classified, graded and managed according to NCI CTCAE v. 4.03.	From signing IC until 30 days after last study treatment